Lupin starts work on a new plant in India; FDA warning letters focus on contamination;

> Lupin, which already operates 11 manufacturing plants in India and Japan, has started construction of a new formulation facility in Mihan, Nagpur, India, which it expects to complete next year. Story

> Dalton Pharma Services in Canada has a contract to manufacture an antiviral agent developed by Defense Research and Development Canada (DRDC), for clinical trials in anticipation of getting the commercial contract later. Item

> An analysis by in-PharmaTechnologist of 2011 FDA warning letters found that a third of agency observations concerned the failure to have written procedures to prevent microbiological contamination. Report

> CRO Reaction Biology Corporation (RBC) has increased its epigenetic production capacity with a new facility in Malvern, PA. Article

> Industrial enzyme developer Codexis has gotten FDA approval for a new production process for manufacturing sitagliptin, the API in Merck's ($MRK) Januvia. More

Suggested Articles

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.